title: A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
abstract: The phosphatidylinositol 3'-kinase (PI3k)/protein kinase B (PKB/Akt) signal transduction pathway plays a critical role in mediating endothelial cell survival and function during oxidative stress. The role of the PI3k/Akt signaling pathway in promoting cell viability was studied in vascular endothelial cells treated with ionizing radiation. Western blot analysis showed that Akt was rapidly phosphorylated in response to radiation in primary culture endothelial cells (human umbilical vascular endothelial cells) in the absence of serum or growth factors. PI3k consists of p85 and p110 subunits, which play a central upstream role in Akt activation in response to exogenous stimuli. The delta isoform of the p110 subunit is expressed in endothelial cells. We studied the effects of the p110delta specific inhibitor IC486068, which abrogated radiation-induced phosphorylation of Akt. IC486068 enhanced radiation-induced apoptosis in endothelial cells and reduced cell migration and tubule formation of endothelial cells in Matrigel following irradiation. In vivo tumor growth delay was studied in mice with Lewis lung carcinoma and GL261 hind limb tumors. Mice were treated with daily i.p. injections (25 mg/kg) of IC486068 during 6 days of radiation treatment (18 Gy). Combined treatment with IC486068 and radiation significantly reduced tumor volume as compared with either treatment alone. Reduction in vasculature was confirmed using the dorsal skinfold vascular window model. The vascular length density was measured by use of the tumor vascular window model and showed IC486068 significantly enhanced radiation-induced destruction of tumor vasculature as compared with either treatment alone. IC486068 enhances radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined with fractionated radiotherapy in murine tumor models. These findings suggest that p110delta is a therapeutic target to enhance radiation-induced tumor control.
authors.affiliation: Department of Radiation Oncology, Vanderbilt University School of Medicine, 1301 22nd Avenue South, The Vanderbilt Clinic, Nashville, TN 37232, USA.
authors.forename: Ling
authors.initials: L
authors.lastname: Geng
authors.forename: Jiahuai
authors.initials: J
authors.lastname: Tan
authors.forename: Eric
authors.initials: E
authors.lastname: Himmelfarb
authors.forename: Aaron
authors.initials: A
authors.lastname: Schueneman
authors.forename: Ken
authors.initials: K
authors.lastname: Niermann
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Brousal
authors.forename: Allie
authors.initials: A
authors.lastname: Fu
authors.forename: Kyle
authors.initials: K
authors.lastname: Cuneo
authors.forename: Edward A
authors.initials: EA
authors.lastname: Kesicki
authors.forename: Jennifer
authors.initials: J
authors.lastname: Treiberg
authors.forename: Joel S
authors.initials: JS
authors.lastname: Hayflick
authors.forename: Dennis E
authors.initials: DE
authors.lastname: Hallahan
mesh_terms: D000818:Animals; D020134:Catalytic Domain; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000188:drug therapy / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; C489253:IC 486068; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines; D011838:Radiation-Sensitizing Agents